- Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have struck a deal with South Africa's Biovac Institute to process and distribute over 100 million doses a year of their COVID-19 vaccine for the African Union beginning in 2022.
- Technical transfer, on-site development, and equipment installation activities will begin immediately.
- Biovac is a public-private partnership focused on vaccine production.
- It will receive COVID-19 vaccine drug substance made in Europe's plants and begin fill-finish operations in 2022.
- Price Action: BNTX stock is up 1.70% at $249.35, while PFE shares are down 1.40% at $40.59 during the market session on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
